Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Accumulated Expenses (2020 - 2022)

Ovid Therapeutics' Other Accumulated Expenses history spans 3 years, with the latest figure at $139167.0 for Q1 2022.

  • For Q1 2022, Other Accumulated Expenses fell 79.33% year-over-year to $139167.0; the TTM value through Mar 2022 reached $139167.0, down 79.33%, while the annual FY2021 figure was $546464.0, 230.12% up from the prior year.
  • Other Accumulated Expenses reached $139167.0 in Q1 2022 per OVID's latest filing, down from $546464.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.0 million in Q2 2021 to a low of $119940.0 in Q3 2021.
  • Average Other Accumulated Expenses over 3 years is $488409.9, with a median of $271314.0 recorded in 2020.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 621.03% in 2021, then tumbled 79.33% in 2022.
  • A 3-year view of Other Accumulated Expenses shows it stood at $165536.0 in 2020, then surged by 230.12% to $546464.0 in 2021, then tumbled by 74.53% to $139167.0 in 2022.
  • Per Business Quant, the three most recent readings for OVID's Other Accumulated Expenses are $139167.0 (Q1 2022), $546464.0 (Q4 2021), and $119940.0 (Q3 2021).